Suppr超能文献

[2016年世界卫生组织分类背景下的肾细胞癌诊断与预后]

[Renal cell carcinoma diagnosis and prognosis within the context of the WHO classification 2016].

作者信息

Zimpfer A, Glass Ä, Zettl H, Maruschke M, Hakenberg O W, Erbersdobler A

机构信息

Institut für Pathologie, Universitätsmedizin Rostock, Strempelstr. 14, 18057, Rostock, Deutschland.

Institut für Biostatistik und Informatik in Medizin und Altersforschung, Universitätsmedizin Rostock, Ernst-Heydemann-Str. 8, 18057, Rostock, Deutschland.

出版信息

Urologe A. 2019 Sep;58(9):1057-1065. doi: 10.1007/s00120-019-0952-z.

Abstract

BACKGROUND

Histological classification of renal cell carcinoma (RCC) has become more and more important for clinical management, but relatively few is known regarding the swiftness with which the 2016 World Health Organization (WHO) classification of RCC was adopted in the daily routine diagnostics.

AIM

To retrospectively review the histological diagnosis of RCC within the context of 2016 WHO classification followed by survival analysis.

MATERIAL AND METHODS

Retrospective register based analysis of RCC diagnosis between 1998 and 2017 and survival analysis.

RESULTS

1440 RCC cases were registered between 1998 and 1917. According to 2016 WHO classification, 77.7% clear cell RCC and 22.3% non-clear cell RCC were diagnosed. A total of 37 rare subtypes were recorded, among those 1% MiT family translocation RCC, 0.35% acquired cystic disease-associated RCC, 0.35% multilocular cystic renal neoplasm of low malignant potential, 0.35% collecting duct carcinoma, 0.3% mucinous tubular and spindle cell carcinoma, 0.1% clear cell papillary RCC and 0.1% RCC with (angio)leiomyomatous stroma. Cox regression analysis showed significant different overall survival and progression-free survival between the histological subtypes.

DISCUSSION

The complexity of the 2016 WHO classification of RCC put high demands on histopathological diagnostics. At University Medicine Center Rostock morphological distinct RCC entities have been mostly diagnosed by conventional means via hematoxillin and eosin stained slides, but beyond immunohistochemistry additionally molecular techniques were established. The histologic subtyping of RCC according to 2016 WHO classification has prognostic significance and might have predictive significance for unique therapeutic approaches.

摘要

背景

肾细胞癌(RCC)的组织学分类对临床管理愈发重要,但对于2016年世界卫生组织(WHO)肾细胞癌分类在日常诊断中被采用的迅速程度,人们了解相对较少。

目的

回顾2016年WHO分类背景下肾细胞癌的组织学诊断,并进行生存分析。

材料与方法

基于回顾性登记分析1998年至2017年肾细胞癌的诊断情况并进行生存分析。

结果

1998年至2017年登记了1440例肾细胞癌病例。根据2016年WHO分类,诊断出77.7%的透明细胞肾细胞癌和22.3%的非透明细胞肾细胞癌。共记录了37种罕见亚型,其中1%为MiT家族易位性肾细胞癌,0.35%为获得性囊性疾病相关性肾细胞癌,0.35%为低恶性潜能多房囊性肾肿瘤,0.35%为集合管癌,0.3%为黏液性管状和梭形细胞癌,0.1%为透明细胞乳头状肾细胞癌,0.1%为伴(血管)平滑肌瘤样间质的肾细胞癌。Cox回归分析显示不同组织学亚型之间的总生存期和无进展生存期存在显著差异。

讨论

2016年WHO肾细胞癌分类的复杂性对组织病理学诊断提出了很高要求。在罗斯托克大学医学中心,形态学上不同的肾细胞癌实体大多通过苏木精和伊红染色切片的传统方法进行诊断,但除免疫组化外还建立了分子技术。根据2016年WHO分类对肾细胞癌进行组织学分型具有预后意义,可能对独特的治疗方法也具有预测意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验